Medigene, Sinphar Pharmaceutical sales and marketing update

Medigene and Sinphar's SynCore Biotechnology Co. Ltd. subsidiary amended a 2011 deal to give SynCore exclusive, commercialization rights to Veregen sinecatechins ointment in Australia, New Zealand and Asia, excluding China and Korea, to treat genital warts. In May 2011, Medigene granted SynCore commercialization rights to Veregen in Taiwan, where the product is under review. SynCore will be responsible for obtaining approval in the regions. Medigene said it is eligible for undisclosed milestones. SynCore could not be reached for details. ...